Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival
Marie Duhamel, Lauranne Drelich, Maxence Wisztorski, Soulaimane Aboulouard, Jean‐Pascal Gimeno, Nina Ogrinc, Patrick Devos, Tristan Cardon, Michael Weller, Fabienne Escande, Fahed Zaïri, Claude‐Alain Maurage, Émilie Le Rhun, Isabelle Fournier, Michel Salzet
Abstract
Molecular heterogeneity is a key feature of glioblastoma that impedes patient stratification and leads to large discrepancies in mean patient survival. Here, we analyze a cohort of 96 glioblastoma patients with survival ranging from a few months to over 4 years. 46 tumors are analyzed by mass spectrometry-based spatially-resolved proteomics guided by mass spectrometry imaging. Integration of protein expression and clinical information highlights three molecular groups associated with immune, neurogenesis, and tumorigenesis signatures with high intra-tumoral heterogeneity. Furthermore, a set of proteins originating from reference and alternative ORFs is found to be statistically significant based on patient survival times. Among these proteins, a 5-protein signature is associated with survival. The expression of these 5 proteins is validated by immunofluorescence on an additional cohort of 50 patients. Overall, our work characterizes distinct molecular regions within glioblastoma tissues based on protein expression, which may help guide glioblastoma prognosis and improve current glioblastoma classification.